# A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer

> **NCT07502014** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Huazhong University of Science and Technology** · enrollment: 60 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (CRC)
- mCRC

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab (QL1706)
- **DRUG:** Fruquintinib
- **RADIATION:** Heterogeneous Radiotherapy

## Key facts

- **NCT ID:** NCT07502014
- **Lead sponsor:** Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502014, "A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07502014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*